SAN JOSE, Calif. — (BUSINESS WIRE) — January 30, 2020 — Cypress Semiconductor Corporation (NASDAQ: CY) today announced its fourth quarter and fiscal year 2019 results with the following highlights:
- Fiscal year revenue of $2.21 billion, down 6.1% year-over-year after adjusting for the divestiture of our NAND business, which was completed on April 1, 2019
- Record Automotive revenue of $829.4 million representing 38% of total fiscal year 2019 revenue
- Fourth quarter revenue was $559.6 million and GAAP and non-GAAP gross margins were 38.0% and 47.1%, respectively
- Fourth quarter GAAP and non-GAAP operating margins were 5.9% and 21.1%, respectively
- Fourth quarter GAAP and non-GAAP diluted EPS were $0.05 and $0.28, respectively
"We continue to see strong adoption of our connect and compute products across the automotive and IoT end-markets, which drove record MCD revenue in fiscal year 2019 in a challenging environment," said Hassane El-Khoury, Cypress’ president and chief executive officer. "We ended the year strongly in the fourth quarter with our automotive revenue achieving a quarterly record and our IoT business up 18% compared to the fourth quarter of 2018. Our focus on maximizing profitability and cashflow continues to pay off as evidenced by our record cash from operations of $479 million in 2019."
As announced on June 3, 2019, Infineon Technologies AG and Cypress entered into an agreement and plan of merger providing for Infineon to acquire Cypress for $23.85 per share in cash, corresponding to an enterprise value of approximately $10 billion. The proposed transaction has received antitrust clearances from authorities in the United States, the European Union, The Philippines, Taiwan, South Korea, and Japan. The parties require approval for the proposed transaction from the Committee on Foreign Investment in the United States (CFIUS) and from China’s State Administration for Market Regulation (SAMR). Due to the pending transaction, Cypress will not hold an earnings conference call and has suspended the practice of providing forward-looking guidance.
Revenue and earnings for the quarter are shown below with comparable periods:
(In thousands, except percentages and per-share data)
|
|
GAAP |
|
NON-GAAP1 |
||||||||||||||||||||
|
|
Q4 2019 |
|
Q3 2019 |
|
Q4 2018 |
|
Q4 2019 |
|
Q3 2019 |
|
Q4 2018 |
||||||||||||
Revenue |
|
$ |
559,568 |
|
|
$ |
574,521 |
|
|
$ |
604,474 |
|
|
$ |
559,568 |
|
|
$ |
574,521 |
|
|
$ |
604,474 |
|
Gross margin |
|
38.0 |
% |
|
37.7 |
% |
|
37.3 |
% |
|
47.1 |
% |
|
46.9 |
% |
|
47.8 |
% |
||||||
Operating margin |
|
5.9 |
% |
|
7.9 |
% |
|
0.5 |
% |
|
21.1 |
% |
|
21.8 |
% |
|
24.5 |
% |
||||||
Net income |
|
$ |
20,760 |
|
|
$ |
12,683 |
|
|
$ |
267,114 |
|
|
$ |
108,394 |
|
|
$ |
115,794 |
|
|
$ |
130,990 |
|
Diluted EPS |
|
$ |
0.05 |
|
|
$ |
0.03 |
|
|
$ |
0.72 |
|
|
$ |
0.28 |
|
|
$ |
0.30 |
|
|
$ |
0.35 |
|
Year-to-date revenue and earnings are shown below with comparable periods:
(In thousands, except percentages and per-share data)
|
|
GAAP |
|
NON-GAAP1 |
||||||||||||
|
|
FY 2019 |
|
FY 2018 |
|
FY 2019 |
|
FY 2018 |
||||||||
Revenue |
|
$ |
2,205,314 |
|
|
$ |
2,483,840 |
|
|
$ |
2,205,314 |
|
|
$ |
2,483,840 |
|
Gross margin |
|
37.6 |
% |
|
37.5 |
% |
|
47.1 |
% |
|
46.8 |
% |
||||
Operating margin |
|
5.6 |
% |
|
6.6 |
% |
|
21.1 |
% |
|
22.8 |
% |
||||
Net income |
|
$ |
40,428 |
|
|
$ |
354,592 |
|
|
$ |
423,531 |
|
|
$ |
508,975 |
|
Diluted EPS |
|
$ |
0.11 |
|
|
$ |
0.95 |
|
|
$ |
1.09 |
|
|
$ |
1.36 |
|
| 1. | See the “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures” tables (“Non-GAAP Results” tables) included below. |
REVENUE SUMMARY (In thousands, except percentages) (Unaudited) |
||||||||||||
|
Three Months Ended |
|
|
|||||||||
|
December 29,
|
|
September 29,
|
|
December 30,
|
|
Sequential
|
|
Year-over-year
|
|||
Business Unit1 |
|
|
|
|
|
|
|
|
|
|||
MCD |
$ |
401,292 |
|
$ |
410,748 |
|
$ |
355,793 |
|
(2.3)% |
|
12.8% |
MPD2 |
158,276 |
|
163,773 |
|
248,681 |
|
(3.4)% |
|
(36.4)% |
|||
Total |
$ |
559,568 |
|
$ |
574,521 |
|
$ |
604,474 |
|
(2.6)% |
|
(7.4)% |
|
Three Months Ended |
||||
|
December 29, 2019 |
|
September 29, 2019 |
|
December 30, 2018 |
End Use |
|
|
|
|
|
IoT |
40.0% |
|
42.6% |
|
31.5% |
Automotive |
39.3% |
|
36.5% |
|
35.5% |
Legacy |
20.7% |
|
20.9% |
|
33.0% |
Total |
100% |
|
100% |
|
100% |
| 1. | The Microcontroller and Connectivity Division ("MCD") includes microcontroller, wireless connectivity and USB products and the Memory Products Division ("MPD") includes RAM, Flash and AgigA Tech products. |
| 2. | MPD revenue for the three months ended December 29, 2019 and September 29, 2019 reflect divestment of our NAND business to a newly formed joint venture, which was completed on April 1, 2019. |
FOLLOW CYPRESS ONLINE
Join the Cypress Developer Community 3.0, read our blog, follow us on Twitter, Facebook and LinkedIn, and watch Cypress videos on our Video Library or YouTube.
ABOUT CYPRESS
Cypress is a leader in advanced embedded solutions for the world’s most innovative automotive, industrial, smart home appliances, consumer electronics and medical products. Cypress’ microcontrollers, analog ICs, wireless and USB-based connectivity solutions and reliable, high-performance memories help engineers design differentiated products and get them to market first. Cypress is committed to providing customers with the best support and development resources on the planet enabling them to disrupt markets by creating new product categories. To learn more, go to www.cypress.com.
NON-GAAP FINANCIAL MEASURES
To supplement its condensed consolidated unaudited financial results presented in accordance with GAAP, Cypress uses the non-GAAP financial measures listed below, which are adjusted from the most directly comparable GAAP financial measures to exclude certain items, as described in more detail below.
- Non-GAAP gross profit;
- Non-GAAP gross margin;
- Non-GAAP cost of revenues;
- Non-GAAP interest and other expense, net;
- Non-GAAP research and development expenses;
- Non-GAAP selling, general and administrative expenses;
- Adjusted EBITDA;
- Non-GAAP income tax provision (benefit);
- Non-GAAP pre-tax profit;
- Non-GAAP pre-tax profit margin;
- Non-GAAP operating income;
- Non-GAAP operating margin;
- Non-GAAP net income;
- Non-GAAP diluted earnings (loss) per share; and
- Free cash flow.
Management believes that these non-GAAP financial measures reflect an additional and useful way of viewing aspects of the Company's operations which, when viewed in conjunction with Cypress' GAAP results, provide a more comprehensive understanding of the various factors and trends affecting the Company's business and operations.
The Company presents non-GAAP financial measures because management uses these measures to analyze and assess the Company's financial results and to manage the business.
There are limitations in using non-GAAP financial measures, including those discussed below. Moreover, the Company’s non-GAAP measures may be calculated differently than the non-GAAP financial measures used by other companies. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the most directly comparable GAAP financial measures. The non-GAAP financial measures supplement and should be viewed in conjunction with GAAP financial measures.
As presented in the Non-GAAP Results tables in this press release, each of the non-GAAP financial measures (other than free cash flow) excludes one or more of the following items:
Acquisition-related charges: Acquisition-related charges are not factored into management's evaluation of Cypress' long-term performance after the completion of acquisitions. However, a limitation of non-GAAP measures that exclude acquisition-related charges is that these charges may represent payments that reduce the cash available to the Company for other purposes. Acquisition-related expenses primarily include:
- Amortization of purchased intangibles, including purchased technology, patents, customer relationships, trademarks, backlog and non-compete agreements;
- Amortization of step-up in value of inventory recorded as part of purchase price accounting; and
- One-time charges associated with the completion of an acquisition including items such as contract termination costs, severance and other acquisition-related restructuring costs; costs incurred in connection with integration activities; and legal and accounting costs.
Stock-based compensation expense: Stock-based compensation expense relates primarily to employee stock options, restricted stock units, performance stock units and the employee stock purchase plan. Stock-based compensation expense is a non-cash expense that is affected by changes in market factors including the price of Cypress’ common shares, which are not within the control of management. In addition, the valuation of stock-based compensation is subjective, and the expense recognized by Cypress may be significantly different than the expense recognized by other companies for similar equity awards, which makes it difficult to assess Cypress’ results compared to its competitors. Accordingly, management excludes this item from its internal operating forecasts and models. However, a limitation of non-GAAP measures that exclude stock-based compensation expense is that they do not reflect the full costs of compensating employees.
Other adjustments: Other items are excluded from non-GAAP financial measures because management does not consider them to be related to the core operating activities and ongoing operating performance of Cypress. Excluding these items, which can vary significantly from quarter to quarter, allows management to better compare Cypress’ period-over-period performance. However, limitations of non-GAAP measures that exclude these items include that these adjustments are often subjective and such non-GAAP measures may not be comparable to similarly titled non-GAAP financial measures used by other companies. Other adjustments primarily include:
- Costs incurred in connection with the proposed merger,
- Impairments of equity-method investments,
- Changes in value of deferred compensation plan assets and liabilities,
- Investment-related gains or losses, including equity method investments,
- Restructuring and related costs,
- Loss on extinguishment of debt,
- Amortization of debt issuance costs, discounts and imputed interest related to the equity component of convertible debt,
- Asset impairments,
- Tax effects of non-GAAP adjustments,
- Income tax adjustment related to the use of the net operating loss, non-cash impact of not asserting indefinite reinvestment on earnings of our foreign subsidiaries, deferred tax expense not affecting taxes payable (i.e. release of valuation allowance), and non-cash expense (benefit) related to uncertain tax positions,
- Certain other expenses and benefits, and
- Diluted weighted average shares non-GAAP adjustment - for purposes of calculating non-GAAP diluted earnings per share, the GAAP diluted weighted average shares outstanding is adjusted to include the impact of non-GAAP adjustments on the number of diluted shares underlying stock-based compensation awards and the impact of the capped call transactions related to the convertible notes.
Adjusted EBITDA: Adjusted EBITDA is calculated by adjusting net income (loss) attributable to Cypress to exclude (without duplication): interest expense, income tax provision, depreciation, amortization, equity in net loss of equity method investees, and the non-GAAP adjustments described above (acquisition related charges, stock-based compensation expense, and other adjustments). Adjusted EBITDA may be useful to management, investors and other users of our financial information because the exclusion of certain gains, losses, and expenses facilitates comparisons of Cypress' operating performance on a period to period basis. Adjusted EBITDA should not be considered as a measure of discretionary cash available to invest in the growth of the business. In addition, adjusted EBITDA should not be considered as a substitute for, or superior to net income attributable to Cypress, operating income, or diluted earnings per share, or other financial measures prepared in accordance with GAAP.
Free Cash Flow: Free cash flow is calculated as net cash provided by (used in) operating activities, less acquisition of property, plant and equipment, net (i.e., acquisition of property, plant and equipment less proceeds received from disposition of property, plant and equipment). We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by business operations, after deducting our net payments for acquisitions and dispositions of property and equipment, which cash can then be used for strategic opportunities or other business purposes including, among others, investing in the Company's business, repurchasing stock, making strategic acquisitions, repayment of debt, and strengthening the balance sheet. A limitation of free cash flow is that it does not represent the total increase or decrease in the cash balance for the period. Management compensates for this limitation by also relying on the net increase in cash and cash equivalents and restricted cash as presented in the Company’s condensed consolidated statements of cash flows prepared in accordance with GAAP which incorporates all cash movements during the period.
FORWARD-LOOKING STATEMENTS
Statements in this press release that are not historical facts and that refer to Cypress or its subsidiaries’ plans and expectations for the future are forward-looking statements as such term is used in the Private Securities Litigation Reform Act of 1995. We may use words such as "may," "will," "should," "plan," "anticipate," "believe," "expect," "future," "intend," "estimate," "predict," "potential," "continue" or similar expressions to identify forward-looking statements. Our forward-looking statements are based on the expectations, beliefs, and intentions of, and the information available to, our executive management on the date of this press release. Forward-looking statements involve risks and uncertainties, and readers are cautioned not to place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement and Plan of Merger (the "Merger Agreement") dated June 3, 2019, by and among Infineon Technologies AG, a stock corporation (Aktiengesellschaft) organized under the laws of the Federal Republic of Germany ("Infineon"), IFX Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Infineon ("Merger Sub") and the Company, pursuant to which Merger Sub will merge with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Infineon; the inability to complete the Merger due to the failure to satisfy conditions to completion of the Merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the Merger; risks related to disruption of management’s attention from our ongoing business operations due to the Merger; the effect of the announcement of the Merger on our relationships with our customers, operating results and business generally; the risk that certain approvals or consents will not be received in a timely manner or that the Merger will not be completed in a timely manner; the impact of the Merger on our ability to retain key employees; the outcome of any legal proceedings related to the Merger; potential tariffs and other disruptions in the international trade and investment environment; global economic and market conditions; our ability to execute on our Cypress 3.0 strategy and our margin improvement plan; risks related to paying down our indebtedness and meeting the covenants in our debt agreements; our efforts to retain and expand our customer base; business conditions and growth trends in the semiconductor market; competition; volatility in supply and demand for our products, including but not limited to the impact of seasonality on supply and demand; our ability to develop, introduce and sell new products and technologies; potential problems relating to our manufacturing activities; reliance on distributors, resellers, third-party manufacturers, and others; risks related to changing relationships with distributors; risks related to our "take or pay" agreements with certain vendors; the risk of defects, errors, or security vulnerabilities in our products; the impact of acquisitions; risks related to our joint venture for NAND flash memory products; the possibility of impairment charges; our ability to attract and retain key personnel; the unpredictability and expense of legal proceedings; the impact of floods, earthquakes, volcanoes, global health pandemics, and other major natural events beyond our control; and other risks and uncertainties described in the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures about Market Risk" sections in our most recent Annual Report on Form 10-K filing and in our subsequent quarterly filings with the U.S. Securities and Exchange Commission (the "SEC") which are available on our investor relations website at http://investors.cypress.com/financial-information/sec-filings. We assume no responsibility to update our forward-looking statements.
Cypress and the Cypress logo are registered trademarks of Cypress Semiconductor Corporation. All other trademarks are property of their owners.
CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) |
||||||||
|
|
December 29, 2019 |
|
December 30, 2018 |
||||
ASSETS |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
415,462 |
|
|
$ |
285,720 |
|
Accounts receivable, net |
|
301,755 |
|
|
324,274 |
|
||
Inventories |
|
297,904 |
|
|
292,093 |
|
||
Assets held for sale |
|
— |
|
|
13,510 |
|
||
Property, plant and equipment, net |
|
258,748 |
|
|
282,986 |
|
||
Goodwill and other intangible assets, net |
|
1,656,933 |
|
|
1,864,340 |
|
||
Other assets |
|
625,312 |
|
|
630,292 |
|
||
Total assets |
|
$ |
3,556,114 |
|
|
$ |
3,693,215 |
|
LIABILITIES AND EQUITY |
|
|
|
|
||||
Accounts payable |
|
$ |
151,393 |
|
|
$ |
210,715 |
|
Income tax liabilities |
|
54,941 |
|
|
53,469 |
|
||
Revenue reserves, deferred margin and other liabilities |
|
523,102 |
|
|
430,814 |
|
||
Current portion of long-term debt |
|
13,615 |
|
|
6,943 |
|
||
Revolving credit facility and long-term debt |
|
712,808 |
|
|
874,235 |
|
||
Total liabilities |
|
1,455,859 |
|
|
1,576,176 |
|
||
Total Cypress stockholders' equity |
|
2,100,255 |
|
|
2,115,734 |
|
||
Non-controlling interest |
|
— |
|
|
1,305 |
|
||
Total equity |
|
2,100,255 |
|
|
2,117,039 |
|
||
Total liabilities and equity |
|
$ |
3,556,114 |
|
|
$ |
3,693,215 |
|
CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ON A GAAP BASIS (In thousands, except per-share data) (Unaudited) |
||||||||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
December 29,
|
|
September 29,
|
|
December 30,
|
|
December 29,
|
|
December 30,
|
||||||||||
Revenues |
|
$ |
559,568 |
|
|
$ |
574,521 |
|
|
$ |
604,474 |
|
|
$ |
2,205,314 |
|
|
$ |
2,483,840 |
|
Cost of revenues |
|
347,150 |
|
|
358,080 |
|
|
379,264 |
|
|
1,375,289 |
|
|
1,552,385 |
|
|||||
Gross profit |
|
212,418 |
|
|
216,441 |
|
|
225,210 |
|
|
830,025 |
|
|
931,455 |
|
|||||
Research and development |
|
91,219 |
|
|
89,253 |
|
|
82,379 |
|
|
362,716 |
|
|
363,996 |
|
|||||
Selling, general and administrative |
|
88,463 |
|
|
81,963 |
|
|
140,091 |
|
|
344,046 |
|
|
403,031 |
|
|||||
Total operating expenses |
|
179,682 |
|
|
171,216 |
|
|
222,470 |
|
|
706,762 |
|
|
767,027 |
|
|||||
Operating income |
|
32,736 |
|
|
45,225 |
|
|
2,740 |
|
|
123,263 |
|
|
164,428 |
|
|||||
Interest and other expense, net |
|
(8,409 |
) |
|
(14,922 |
) |
|
(20,489 |
) |
|
(44,577 |
) |
|
(67,845 |
) |
|||||
Income (loss) before income taxes and non-controlling interest |
|
24,327 |
|
|
30,303 |
|
|
(17,749 |
) |
|
78,686 |
|
|
96,583 |
|
|||||
Income tax benefit (provision) |
|
(5,044 |
) |
|
(16,247 |
) |
|
331,447 |
|
|
(2,372 |
) |
|
315,618 |
|
|||||
Share in gain/loss, net and impairment of equity method investees |
|
1,477 |
|
|
(1,383 |
) |
|
(46,497 |
) |
|
(35,901 |
) |
|
(57,370 |
) |
|||||
Net income |
|
20,760 |
|
|
12,673 |
|
|
267,201 |
|
|
40,413 |
|
|
354,831 |
|
|||||
Net loss (income) attributable to non-controlling interest |
|
— |
|
|
10 |
|
|
(87 |
) |
|
15 |
|
|
(239 |
) |
|||||
Net income attributable to Cypress |
|
$ |
20,760 |
|
|
$ |
12,683 |
|
|
$ |
267,114 |
|
|
$ |
40,428 |
|
|
$ |
354,592 |
|
Net income per share attributable to Cypress: |
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic |
|
$ |
0.06 |
|
|
$ |
0.03 |
|
|
$ |
0.74 |
|
|
$ |
0.11 |
|
|
$ |
0.99 |
|
Diluted |
|
$ |
0.05 |
|
|
$ |
0.03 |
|
|
$ |
0.72 |
|
|
$ |
0.11 |
|
|
$ |
0.95 |
|
Cash dividend declared per share |
|
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.44 |
|
Shares used in net income per share calculation: |
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic |
|
370,846 |
|
|
369,241 |
|
|
361,616 |
|
|
367,308 |
|
|
359,324 |
|
|||||
Diluted |
|
390,952 |
|
|
388,243 |
|
|
369,638 |
|
|
384,670 |
|
|
372,178 |
|
|||||
CYPRESS SEMICONDUCTOR CORPORATION RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES (In thousands, except percentages and per-share data) (Unaudited) |
||||||||||||||||
Table A: GAAP to Non-GAAP reconciling items: Three Months Ended Q4 2019 |
||||||||||||||||
|
|
Cost of
|
|
Research and
|
|
Selling,
|
|
Interest and
|
||||||||
GAAP [i] |
|
$ |
347,150 |
|
|
$ |
91,219 |
|
|
$ |
88,463 |
|
|
$ |
(6,932 |
) |
[1] Stock-based compensation, including costs related to modification of equity awards |
|
4,035 |
|
|
7,010 |
|
|
19,171 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
213 |
|
|
1,318 |
|
|
1,271 |
|
|
(2,747 |
) |
||||
[3] Gain on sale of NAND business to joint venture |
|
(120 |
) |
|
— |
|
|
— |
|
|
— |
|
||||
[4] Share in gain/loss, net of equity method investees |
|
— |
|
|
— |
|
|
— |
|
|
(1,477 |
) |
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
3,025 |
|
||||
[6] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
496 |
|
||||
[8] Amortization of acquisition-related intangible assets and other |
|
47,085 |
|
|
— |
|
|
4,309 |
|
|
— |
|
||||
[9] Restructuring charges and other |
|
(22 |
) |
|
(493 |
) |
|
10 |
|
|
— |
|
||||
[10] Merger-related expenses |
|
— |
|
|
— |
|
|
1,302 |
|
|
— |
|
||||
Non - GAAP [ii] |
|
$ |
295,959 |
|
|
$ |
83,384 |
|
|
$ |
62,400 |
|
|
$ |
(7,635 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(51,191 |
) |
|
$ |
(7,835 |
) |
|
$ |
(26,063 |
) |
|
$ |
(703 |
) |
Table B: GAAP to Non-GAAP reconciling items: Three Months Ended Q3 2019 |
||||||||||||||||
|
|
Cost of
|
|
Research and
|
|
Selling,
|
|
Interest and
|
||||||||
GAAP [i] |
|
$ |
358,080 |
|
|
$ |
89,253 |
|
|
$ |
81,963 |
|
|
$ |
(16,305 |
) |
[1] Stock-based compensation |
|
5,907 |
|
|
7,708 |
|
|
11,276 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
(6 |
) |
|
(38 |
) |
|
(37 |
) |
|
237 |
|
||||
[3] Gain on sale of NAND business to joint venture |
|
— |
|
|
— |
|
|
— |
|
|
(1,887 |
) |
||||
[4] Share in gain/loss, net of equity method investees |
|
— |
|
|
— |
|
|
— |
|
|
1,383 |
|
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
3,101 |
|
||||
[6] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
626 |
|
||||
[7] Loss on extinguishment of debt |
|
— |
|
|
— |
|
|
— |
|
|
6,402 |
|
||||
[8] Amortization of acquisition-related intangible assets and other |
|
47,084 |
|
|
— |
|
|
4,310 |
|
|
— |
|
||||
[9] Restructuring charges |
|
(68 |
) |
|
291 |
|
|
169 |
|
|
— |
|
||||
[10] Merger-related expenses |
|
— |
|
|
— |
|
|
3,043 |
|
|
— |
|
||||
[11] Other income and expenses |
|
— |
|
|
280 |
|
|
381 |
|
|
(631 |
) |
||||
Non - GAAP [ii] |
|
$ |
305,163 |
|
|
$ |
81,012 |
|
|
$ |
62,821 |
|
|
$ |
(7,074 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(52,917 |
) |
|
$ |
(8,241 |
) |
|
$ |
(19,142 |
) |
|
$ |
9,231 |
|
Table C: GAAP to Non-GAAP reconciling items: Three Months Ended Q4 2018 |
||||||||||||||||
|
|
Cost of
|
|
Research and
|
|
Selling,
|
|
Interest and
|
||||||||
GAAP [i] |
|
$ |
379,264 |
|
|
$ |
82,379 |
|
|
$ |
140,091 |
|
|
$ |
(66,986 |
) |
[1] Stock based compensation |
|
3,842 |
|
|
6,395 |
|
|
9,166 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
(468 |
) |
|
(2,377 |
) |
|
(2,726 |
) |
|
5,401 |
|
||||
[3] Loss on assets held for sale¹ |
|
10,869 |
|
|
— |
|
|
65,722 |
|
|
— |
|
||||
[4] Share in net loss and impairment of equity method investees² |
|
— |
|
|
— |
|
|
— |
|
|
46,496 |
|
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
3,338 |
|
||||
[6] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
908 |
|
||||
[7] Amortization of intangible assets |
|
49,583 |
|
|
— |
|
|
4,310 |
|
|
— |
|
||||
[8] Litigation settlement and other |
|
— |
|
|
(309 |
) |
|
(159 |
) |
|
159 |
|
||||
[9] Restructuring charges |
|
135 |
|
|
944 |
|
|
437 |
|
|
— |
|
||||
Non - GAAP [ii] |
|
$ |
315,303 |
|
|
$ |
77,726 |
|
|
$ |
63,341 |
|
|
$ |
(10,684 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(63,961 |
) |
|
$ |
(4,653 |
) |
|
$ |
(76,750 |
) |
|
$ |
56,302 |
|
| 1. | Relates to our entry into a definitive agreement to divest the NAND business |
| 2. | Includes $41.5 million impairment charge recorded for the investment in Deca Technologies, Inc. |
Table D: GAAP to Non-GAAP reconciling items: Twelve Months Ended Q4 2019 |
||||||||||||||||
|
||||||||||||||||
|
|
Cost of
|
|
Research and
|
|
Selling,
|
|
Interest and
|
||||||||
GAAP [i] |
|
$ |
1,375,289 |
|
|
$ |
362,716 |
|
|
$ |
344,046 |
|
|
$ |
(80,478 |
) |
[1] Stock based compensation, including costs related to modification of equity awards |
|
15,443 |
|
|
33,702 |
|
|
56,837 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
807 |
|
|
4,116 |
|
|
4,120 |
|
|
(7,989 |
) |
||||
[3] Loss (gain) from sale of NAND business to joint venture |
|
1,897 |
|
|
— |
|
|
1,515 |
|
|
(1,887 |
) |
||||
[4] Share in gain/loss, net and impairment of equity method investees1 |
|
— |
|
|
— |
|
|
— |
|
|
35,901 |
|
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
12,770 |
|
||||
[6] Amortization of debt issuance costs |
|
— |
|
|
— |
|
|
— |
|
|
2,980 |
|
||||
[7] Loss on extinguishment of debt |
|
— |
|
|
— |
|
|
— |
|
|
6,402 |
|
||||
[8] Amortization of acquisition-related intangible assets and other |
|
189,679 |
|
|
— |
|
|
17,233 |
|
|
— |
|
||||
[9] Restructuring charges and other |
|
880 |
|
|
1,160 |
|
|
918 |
|
|
— |
|
||||
[10] Merger-related expenses |
|
— |
|
|
— |
|
|
12,754 |
|
|
— |
|
||||
[11] Other income and expenses |
|
— |
|
|
337 |
|
|
861 |
|
|
(433 |
) |
||||
Non - GAAP [ii] |
|
$ |
1,166,583 |
|
|
$ |
323,401 |
|
|
$ |
249,808 |
|
|
$ |
(32,734 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(208,706 |
) |
|
$ |
(39,315 |
) |
|
$ |
(94,238 |
) |
|
$ |
47,744 |
|
1. Includes a $29.5 million impairment charge recorded for the investment in Deca Technologies, Inc. |
||||||||||||||||
Table E: GAAP to Non-GAAP reconciling items: Twelve Months Ended Q4 2018 |
||||||||||||||||
|
|
Cost of
|
|
Research and
|
|
Selling,
|
|
Interest and
|
||||||||
GAAP [i] |
|
$ |
1,552,385 |
|
|
$ |
363,996 |
|
|
$ |
403,031 |
|
|
$ |
(125,215 |
) |
[1] Stock based compensation, including costs related to modification of equity awards |
|
16,531 |
|
|
35,115 |
|
|
44,319 |
|
|
— |
|
||||
[2] Changes in value of deferred compensation plan |
|
(169 |
) |
|
(971 |
) |
|
(1,036 |
) |
|
2,904 |
|
||||
[3] Share in gain/loss, net and impairment of equity method investees¹ |
|
— |
|
|
— |
|
|
— |
|
|
57,369 |
|
||||
[4] Amortization of intangible assets |
|
200,024 |
|
|
— |
|
|
18,125 |
|
|
— |
|
||||
[5] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
— |
|
|
— |
|
|
— |
|
|
17,966 |
|
||||
[6] Amortization of debt issuance cost |
|
— |
|
|
— |
|
|
— |
|
|
1,981 |
|
||||
[7] Settlement and other charges |
|
— |
|
|
(309 |
) |
|
(645 |
) |
|
(1,111 |
) |
||||
[8] Restructuring charges |
|
3,271 |
|
|
1,785 |
|
|
11,785 |
|
|
— |
|
||||
[9] Loss on extinguishment of Spansion convertible notes |
|
— |
|
|
— |
|
|
— |
|
|
3,258 |
|
||||
[10] Loss on assets held for sale² |
|
10,869 |
|
|
— |
|
|
65,722 |
|
|
— |
|
||||
[11] Gain on sale on cost method investment |
|
— |
|
|
— |
|
|
(1,521 |
) |
|
— |
|
||||
Non - GAAP [ii] |
|
$ |
1,321,859 |
|
|
$ |
328,376 |
|
|
$ |
266,282 |
|
|
$ |
(42,848 |
) |
Impact of reconciling items [ii - i] |
|
$ |
(230,526 |
) |
|
$ |
(35,620 |
) |
|
$ |
(136,749 |
) |
|
$ |
82,367 |
|
1. Includes $41.5 million impairment charge recorded for the investment in Deca Technologies Inc. |
||||||||||||||||
2. Relates to our entry into a definitive agreement to divest the NAND business |
||||||||||||||||
Table F: Non-GAAP gross profit |
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
||||||||||
GAAP gross profit |
|
$ |
212,418 |
|
|
$ |
216,441 |
|
|
$ |
225,210 |
|
|
$ |
830,025 |
|
|
$ |
931,455 |
|
Impact of reconciling items on cost of revenues (Table A, B, C, D and E) |
|
51,191 |
|
|
52,917 |
|
|
63,961 |
|
|
208,706 |
|
|
230,526 |
|
|||||
Non-GAAP gross profit |
|
$ |
263,609 |
|
|
$ |
269,358 |
|
|
$ |
289,171 |
|
|
$ |
1,038,731 |
|
|
$ |
1,161,981 |
|
GAAP gross margin (GAAP gross profit/revenue) |
|
38.0 |
% |
|
37.7 |
% |
|
37.3 |
% |
|
37.6 |
% |
|
37.5 |
% |
|||||
Non-GAAP gross margin (Non-GAAP gross profit/revenue) |
|
47.1 |
% |
|
46.9 |
% |
|
47.8 |
% |
|
47.1 |
% |
|
46.8 |
% |
|||||
Table G: Non-GAAP operating income |
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
||||||||||
GAAP operating income [i] |
|
$ |
32,736 |
|
|
$ |
45,225 |
|
|
$ |
2,740 |
|
|
$ |
123,263 |
|
|
$ |
164,428 |
|
Impact of reconciling items on cost of revenues (see Table A, B, C, D and E) |
|
51,191 |
|
|
52,917 |
|
|
63,961 |
|
|
208,706 |
|
|
230,526 |
|
|||||
Impact of reconciling items on R&D (see Tables A, B, C, D and E) |
|
7,835 |
|
|
8,241 |
|
|
4,653 |
|
|
39,315 |
|
|
35,620 |
|
|||||
Impact of reconciling items on SG&A (see Tables A, B, C, D and E) |
|
26,063 |
|
|
19,142 |
|
|
76,750 |
|
|
94,238 |
|
|
136,749 |
|
|||||
Non-GAAP operating income [ii] |
|
$ |
117,825 |
|
|
$ |
125,525 |
|
|
$ |
148,104 |
|
|
$ |
465,522 |
|
|
$ |
567,323 |
|
Impact of reconciling items on operating income [ii - i] |
|
$ |
85,089 |
|
|
$ |
80,300 |
|
|
$ |
145,364 |
|
|
$ |
342,259 |
|
|
$ |
402,895 |
|
GAAP operating margin (GAAP operating income / revenue) |
|
5.9 |
% |
|
7.9 |
% |
|
0.5 |
% |
|
5.6 |
% |
|
6.6 |
% |
|||||
Non-GAAP operating margin (Non-GAAP operating income / revenue) |
|
21.1 |
% |
|
21.8 |
% |
|
24.5 |
% |
|
21.1 |
% |
|
22.8 |
% |
|||||
Table H: Non-GAAP pre-tax profit |
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
||||||||||
GAAP (loss) income before income taxes and non-controlling interest ("Pre-tax income") |
|
$ |
24,327 |
|
|
$ |
30,303 |
|
|
$ |
(17,749 |
) |
|
$ |
78,686 |
|
|
$ |
96,583 |
|
Share in gain/loss, net and impairment of equity method investees1 |
|
1,477 |
|
|
(1,383 |
) |
|
(46,497 |
) |
|
(35,901 |
) |
|
(57,370 |
) |
|||||
Impact of reconciling items on operating income (see Table G) |
|
85,089 |
|
|
80,300 |
|
|
145,364 |
|
|
342,259 |
|
|
402,895 |
|
|||||
Impact of reconciling items on interest and other expense, net (see Table A, B, C, D and E) |
|
(703 |
) |
|
9,231 |
|
|
56,302 |
|
|
47,744 |
|
|
82,367 |
|
|||||
Non-GAAP pre-tax profit |
|
$ |
110,190 |
|
|
$ |
118,451 |
|
|
$ |
137,420 |
|
|
$ |
432,788 |
|
|
$ |
524,475 |
|
GAAP pre-tax profit margin (GAAP pre-tax income/revenue) |
|
4.3 |
% |
|
5.3 |
% |
|
(2.9 |
)% |
|
3.6 |
% |
|
3.9 |
% |
|||||
Non-GAAP pre-tax profit margin (Non-GAAP pre-tax profit/revenue) |
|
19.7 |
% |
|
20.6 |
% |
|
22.7 |
% |
|
19.6 |
% |
|
21.1 |
% |
|||||
1. |
The three months ended Q4'18 includes $41.5 million, and the twelve months ended Q4'19 and Q4'18 include $29.5 million and $41.5 million, respectively, of impairment charge recorded for the investment in Deca Technologies Inc. |
Table I: Non-GAAP income tax expense |
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
|||||||||||||||
GAAP income tax (benefit) provision [i] |
|
$ |
|
5,044 |
|
|
$ |
|
16,247 |
|
|
$ |
|
(331,447 |
) |
|
$ |
|
2,372 |
|
|
$ |
|
(315,618 |
) |
[1] Tax impact of non-GAAP adjustments* relating to: |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
[a] Stock-based compensation |
|
|
6,345 |
|
|
|
5,227 |
|
|
|
4,075 |
|
|
|
22,256 |
|
|
|
20,152 |
|
|||||
[b] Changes in value of deferred compensation plan |
|
|
12 |
|
|
|
32 |
|
|
|
(36 |
) |
|
|
221 |
|
|
|
153 |
|
|||||
[c] Share in gain/loss, net and impairment of equity method investees |
|
|
(310 |
) |
|
|
290 |
|
|
|
9,764 |
|
|
|
7,539 |
|
|
|
12,047 |
|
|||||
[d] Imputed interest on convertible debt, equity component amortization on convertible debt and others |
|
|
636 |
|
|
|
651 |
|
|
|
892 |
|
|
|
2,682 |
|
|
|
3,964 |
|
|||||
[e] Amortization of debt issuance costs |
|
|
104 |
|
|
|
131 |
|
|
— |
|
|
|
625 |
|
|
|
225 |
|
||||||
[f] Amortization of acquisition-related intangible assets and other |
|
|
10,793 |
|
|
|
10,793 |
|
|
|
11,202 |
|
|
|
43,452 |
|
|
|
45,696 |
|
|||||
[g] Restructuring and other charges |
|
|
(105 |
) |
|
|
82 |
|
|
|
318 |
|
|
|
618 |
|
|
|
3,537 |
|
|||||
[h] Other (income) and expenses |
|
— |
|
|
|
6 |
|
|
— |
|
|
|
165 |
|
|
— |
|
||||||||
[i] Loss on extinguishment of debt |
|
— |
|
|
|
1,344 |
|
|
|
16,084 |
|
|
|
1,344 |
|
|
|
16,768 |
|
||||||
[j] (Gain) loss on sale of NAND business to joint venture |
|
|
(25 |
) |
|
|
(396 |
) |
|
— |
|
|
|
321 |
|
|
— |
|
|||||||
[k] Merger, integration, related costs and adjustments related to assets held for sale |
|
— |
|
|
— |
|
|
|
57 |
|
|
— |
|
|
|
57 |
|
||||||||
[l] Settlement charges |
|
— |
|
|
— |
|
|
|
(6 |
) |
|
— |
|
|
|
(6 |
) |
||||||||
[m] Gain on sale of cost method investment |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
(319 |
) |
|||||||||
[n] Merger-related expenses |
|
|
273 |
|
|
|
639 |
|
|
— |
|
|
|
2,678 |
|
|
— |
|
|||||||
[2] Uncertain tax positions |
|
|
1,027 |
|
|
|
(6,675 |
) |
|
|
(3,945 |
) |
|
|
(2,730 |
) |
|
|
(8,815 |
) |
|||||
[3] Valuation allowance release, utilization of NOLs including excess tax benefits, and others** |
|
|
(21,998 |
) |
|
|
(25,704 |
) |
|
|
299,385 |
|
|
|
(72,271 |
) |
|
|
237,420 |
|
|||||
Non-GAAP income tax expense [ii]* |
|
$ |
|
1,796 |
|
|
$ |
|
2,667 |
|
|
$ |
|
6,343 |
|
|
$ |
|
9,272 |
|
|
$ |
|
15,261 |
|
Impact of reconciling items on income tax provision [i - ii] |
|
$ |
|
3,248 |
|
|
$ |
|
13,580 |
|
|
$ |
|
(337,790 |
) |
|
$ |
|
(6,900 |
) |
|
$ |
|
(330,879 |
) |
*Tax impact of Non-GAAP adjustments is calculated by using the federal statutory rate of 21%. |
|||||||||||||||||||||||||
** Other items include but are not limited to deferred tax expense not affecting income tax payable. |
|||||||||||||||||||||||||
Table J: Non-GAAP net income |
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
|||||||||||||||
GAAP net income attributable to Cypress |
|
$ |
|
20,760 |
|
|
$ |
|
12,683 |
|
|
$ |
|
267,114 |
|
|
$ |
|
40,428 |
|
|
$ |
|
354,592 |
|
Impact of reconciling items on operating income (see Table G) |
|
|
85,089 |
|
|
|
80,300 |
|
|
|
145,364 |
|
|
|
342,259 |
|
|
|
402,895 |
|
|||||
Impact of reconciling items on interest and other expense, net (see Table A, B, C, D, and E) |
|
|
(703 |
) |
|
|
9,231 |
|
|
|
56,302 |
|
|
|
47,744 |
|
|
|
82,367 |
|
|||||
Impact of reconciling items on income tax provision (see Table I) |
|
|
3,248 |
|
|
|
13,580 |
|
|
|
(337,790 |
) |
|
|
(6,900 |
) |
|
|
(330,879 |
) |
|||||
Non-GAAP net income |
|
$ |
|
108,394 |
|
|
$ |
|
115,794 |
|
|
$ |
|
130,990 |
|
|
$ |
|
423,531 |
|
|
$ |
|
508,975 |
|
Table K: Weighted-average shares, diluted |
|
Three Months Ended |
||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
||||||||||||
|
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
||||||
Weighted-average common shares outstanding, basic |
|
370,846 |
|
|
370,846 |
|
|
369,241 |
|
|
369,241 |
|
|
361,616 |
|
|
361,616 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Stock options, unvested restricted stock and other |
|
8,503 |
|
|
11,361 |
|
|
7,862 |
|
|
11,704 |
|
|
6,482 |
|
|
11,709 |
|
Convertible notes |
|
11,603 |
|
|
9,982 |
|
|
11,140 |
|
|
9,480 |
|
|
1,540 |
|
|
1,540 |
|
Weighted-average common shares outstanding, diluted |
|
390,952 |
|
|
392,189 |
|
|
388,243 |
|
|
390,425 |
|
|
369,638 |
|
|
374,865 |
|
Table L: Weighted-average shares, diluted |
|
Twelve Months Ended |
||||||||||
|
|
Q4'19 |
|
Q4'18 |
||||||||
|
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
||||
Weighted-average common shares outstanding, basic |
|
367,308 |
|
|
367,308 |
|
|
359,324 |
|
|
359,324 |
|
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
||||
Stock options, unvested restricted stock and other |
|
8,724 |
|
|
12,995 |
|
|
7,754 |
|
|
13,319 |
|
Convertible notes |
|
8,638 |
|
|
6,716 |
|
|
5,100 |
|
|
2,705 |
|
Weighted-average common shares outstanding, diluted |
|
384,670 |
|
|
387,019 |
|
|
372,178 |
|
|
375,348 |
|
Table M: Earnings per share |
|
Three Months Ended |
||||||||||||||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
||||||||||||||||||||||||
|
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
||||||||||||||||||
Net income (see Table J) [i] |
|
$ |
|
20,760 |
|
|
$ |
|
108,394 |
|
|
$ |
|
12,683 |
|
|
$ |
|
115,794 |
|
|
$ |
|
267,114 |
|
|
$ |
|
130,990 |
|
Weighted-average common shares outstanding, diluted (see Table K) [ii] |
|
|
390,952 |
|
|
|
392,189 |
|
|
|
388,243 |
|
|
|
390,425 |
|
|
|
369,638 |
|
|
|
374,865 |
|
||||||
Earnings per share - diluted [i/ii] |
|
$ |
|
0.05 |
|
|
$ |
|
0.28 |
|
|
$ |
|
0.03 |
|
|
$ |
|
0.30 |
|
|
$ |
|
0.72 |
|
|
$ |
|
0.35 |
|
Table N: Earnings per share |
|
Twelve Months Ended |
||||||||||||||||||
|
|
Q4'19 |
|
Q4'18 |
||||||||||||||||
|
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
||||||||||||
Net income (see Table J) [i] |
|
$ |
|
40,428 |
|
|
$ |
|
423,531 |
|
|
$ |
|
354,592 |
|
|
$ |
|
508,975 |
|
Weighted-average common shares outstanding, diluted (see Table L) [ii] |
|
|
384,670 |
|
|
|
387,019 |
|
|
|
372,178 |
|
|
|
375,348 |
|
||||
Earnings per share - diluted [i/ii] |
|
$ |
|
0.11 |
|
|
$ |
|
1.09 |
|
|
$ |
|
0.95 |
|
|
$ |
|
1.36 |
|
Table O: Adjusted EBITDA |
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
|||||||||||||||
GAAP net income attributable to Cypress |
|
$ |
|
20,760 |
|
|
$ |
|
12,683 |
|
|
$ |
|
267,114 |
|
|
$ |
|
40,428 |
|
|
$ |
|
354,592 |
|
Interest and other expense, net |
|
|
(8,409 |
) |
|
|
(14,922 |
) |
|
|
(20,489 |
) |
|
|
(44,577 |
) |
|
|
(67,845 |
) |
|||||
Income tax benefit (provision) |
|
|
(5,044 |
) |
|
|
(16,247 |
) |
|
|
331,447 |
|
|
|
(2,372 |
) |
|
|
315,618 |
|
|||||
Share in gain/loss, net and impairment of equity method investees1 |
|
|
1,477 |
|
|
|
(1,383 |
) |
|
|
(46,497 |
) |
|
|
(35,901 |
) |
|
|
(57,370 |
) |
|||||
Net gain (loss) attributable to non-controlling interests |
|
— |
|
|
|
10 |
|
|
|
(87 |
) |
|
|
15 |
|
|
|
(239 |
) |
||||||
GAAP operating income |
|
$ |
|
32,736 |
|
|
$ |
|
45,225 |
|
|
$ |
|
2,740 |
|
|
$ |
|
123,263 |
|
|
$ |
|
164,428 |
|
Impact of reconciling items on operating income (see Table G) |
|
|
85,089 |
|
|
|
80,300 |
|
|
|
145,364 |
|
|
|
342,259 |
|
|
|
402,895 |
|
|||||
Non-GAAP operating income |
|
$ |
|
117,825 |
|
|
$ |
|
125,525 |
|
|
$ |
|
148,104 |
|
|
$ |
|
465,522 |
|
|
$ |
|
567,323 |
|
Depreciation |
|
|
19,282 |
|
|
|
19,060 |
|
|
|
16,527 |
|
|
|
77,248 |
|
|
|
66,299 |
|
|||||
Adjusted EBITDA |
|
$ |
|
137,107 |
|
|
$ |
|
144,585 |
|
|
$ |
|
164,631 |
|
|
$ |
|
542,770 |
|
|
$ |
|
633,622 |
|
1. |
The three months ended Q4'18 includes $41.5 million, and the twelve months ended Q4'19 and Q4'18 include $29.5 million and $41.5 million, respectively, of impairment charge recorded for the investment in Deca Technologies Inc. |
Table P: Free cash flow |
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||||||||||||
|
|
Q4'19 |
|
Q3'19 |
|
Q4'18 |
|
Q4'19 |
|
Q4'18 |
|||||||||||||||
GAAP net cash provided by operating activities |
|
$ |
|
234,246 |
|
|
$ |
|
64,497 |
|
|
$ |
|
142,215 |
|
|
$ |
|
478,915 |
|
|
$ |
|
471,700 |
|
Acquisition of property, plant and equipment, net |
|
|
(12,063 |
) |
|
|
(10,599 |
) |
|
|
(5,069 |
) |
|
|
(40,686 |
) |
|
|
(63,130 |
) |
|||||
Free cash flow |
|
$ |
|
222,183 |
|
|
$ |
|
53,898 |
|
|
$ |
|
137,146 |
|
|
$ |
|
438,229 |
|
|
$ |
|
408,570 |
|
CYPRESS SEMICONDUCTOR CORPORATION SUPPLEMENTAL FINANCIAL DATA (In thousands except financial ratios and per-share amounts) (Unaudited) |
||||||||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
|
December 29,
|
|
September 29,
|
|
December 30,
|
|
December 29,
|
|
December 30,
|
||||||||||
Selected Cash Flow Data (Preliminary): |
|
|
|
|
|
|
|
|
|
|
||||||||||
Net cash provided by operating activities |
|
$ |
234,246 |
|
|
$ |
64,497 |
|
|
$ |
142,215 |
|
|
$ |
478,915 |
|
|
$ |
471,700 |
|
Net cash used in investing activities |
|
$ |
(14,058 |
) |
|
$ |
(2,056 |
) |
|
$ |
(5,988 |
) |
|
$ |
(27,311 |
) |
|
$ |
(49,690 |
) |
Net cash used in financing activities |
|
$ |
(147,754 |
) |
|
$ |
(91,594 |
) |
|
$ |
(55,252 |
) |
|
$ |
(321,862 |
) |
|
$ |
(287,886 |
) |
Other Supplemental Data (Preliminary): |
|
|
|
|
|
|
|
|
|
|
||||||||||
Capital expenditures, net |
|
$ |
12,063 |
|
|
$ |
10,599 |
|
|
$ |
5,069 |
|
|
$ |
40,686 |
|
|
$ |
63,130 |
|
Depreciation |
|
$ |
19,282 |
|
|
$ |
19,060 |
|
|
$ |
16,527 |
|
|
$ |
77,248 |
|
|
$ |
66,299 |
|
Payment of dividend |
|
$ |
40,679 |
|
|
$ |
40,289 |
|
|
$ |
39,772 |
|
|
$ |
160,850 |
|
|
$ |
157,364 |
|
Dividend paid per share |
|
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.44 |
|
Total debt (principal amount) |
|
$ |
758,632 |
|
|
$ |
856,102 |
|
|
$ |
935,838 |
|
|
$ |
758,632 |
|
|
$ |
935,838 |
|
Net leverage ratio¹ |
|
0.63 |
|
|
0.90 |
|
|
1.03 |
|
|
0.63 |
|
|
1.03 |
|
|||||
Cash Income Tax |
|
$ |
1,796 |
|
|
$ |
2,667 |
|
|
$ |
6,343 |
|
|
$ |
9,272 |
|
|
$ |
15,261 |
|
1. Total debt (principal amount) less cash / Last 12 months Adjusted EBITDA |
||||||||||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005810/en/
Contact:
Thad Trent
EVP Finance & Administration and CFO
(408) 943-2925
David Szabados
Senior Public Relations Manager
(408) 544-1473